Trifoli 5 Tablet contains Trioxsalen 5 mg, a photosensitizing medicine used in combination with controlled ultraviolet A (UVA) light therapy for the management of specific dermatological conditions. The medicine enhances the skin's sensitivity to ultraviolet light, helping improve therapeutic outcomes in selected pigmentary and skin disorders. It is prescribed under the supervision of dermatology specialists as part of a carefully monitored photochemotherapy treatment program.
Trioxsalen belongs to the psoralen class of medicines and works by interacting with skin cells when exposed to UVA radiation. This process helps influence skin pigmentation and cellular activity, making it useful in the management of conditions where controlled phototherapy is beneficial. The medicine plays an important role in PUVA (Psoralen + UVA) therapy, a well-established treatment approach in dermatology for selected skin disorders.
The tablet is commonly indicated for vitiligo and may also be used in certain other dermatological conditions as determined by a healthcare professional. When administered in conjunction with properly supervised UVA exposure, it helps support repigmentation and improve skin appearance in appropriate patients. Treatment schedules are individualized according to the patient's condition, skin response, and therapeutic requirements.
With the increasing demand for specialized dermatological treatments and advanced phototherapy solutions, Trifoli 5 Tablet maintains a valuable position in the dermatology segment. Its established role in PUVA therapy, physician acceptance, and continued relevance in pigmentary disorder management contribute to steady market demand. The product offers attractive business opportunities and sustainable growth potential for retailers and distributors operating within the dermatology pharmaceutical sector.